Esperion Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, ESPR, Esperion Therapeutics Inc, priceseries

Esperion Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
4.21
Close
4.12
High
4.21
Low
3.81
Previous Close
4.24
Daily Price Gain
-0.12
YTD High
5.28
YTD High Date
Jan 4, 2022
YTD Low
3.28
YTD Low Date
Feb 8, 2022
YTD Price Change
-1.07
YTD Gain
-20.62%
52 Week High
32.00
52 Week High Date
Mar 16, 2021
52 Week Low
3.28
52 Week Low Date
Feb 8, 2022
52 Week Price Change
-25.10
52 Week Gain
-85.90%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 31. 2017
12.12
Mar 16. 2017
29.45
31 Trading Days
143.03%
Link
LONG
Mar 20. 2017
41.22
Mar 21. 2017
44.72
1 Trading Days
8.48%
Link
LONG
Jun 21. 2017
41.02
Jul 19. 2017
46.00
19 Trading Days
12.13%
Link
LONG
Nov 20. 2017
53.16
Dec 5. 2017
58.70
10 Trading Days
10.43%
Link
LONG
Feb 13. 2018
69.99
Mar 1. 2018
77.54
11 Trading Days
10.79%
Link
LONG
Oct 31. 2018
45.43
Nov 12. 2018
52.07
8 Trading Days
14.61%
Link
LONG
May 3. 2019
43.24
May 29. 2019
49.97
17 Trading Days
15.55%
Link
LONG
Nov 15. 2019
40.47
Dec 5. 2019
48.73
13 Trading Days
20.40%
Link
LONG
Dec 18. 2019
52.68
Jan 10. 2020
59.63
15 Trading Days
13.20%
Link
LONG
Feb 7. 2020
61.74
Feb 21. 2020
65.88
9 Trading Days
6.71%
Link
LONG
Apr 16. 2020
35.86
Apr 30. 2020
39.61
10 Trading Days
10.46%
Link
LONG
May 5. 2020
40.54
May 14. 2020
44.94
7 Trading Days
10.86%
Link
LONG
Jan 25. 2021
28.80
Feb 9. 2021
33.42
11 Trading Days
16.05%
Link
LONG
Jun 7. 2021
21.17
Jun 21. 2021
24.35
10 Trading Days
15.00%
Link
LONG
Oct 29. 2021
8.94
Nov 9. 2021
9.91
7 Trading Days
10.85%
Link
Company Information
Stock Symbol
ESPR
Exchange
NasdaqGM
Company URL
http://www.esperion.com
Company Phone
734-887-3903
CEO
Tim M. Mayleben
Headquarters
Michigan
Business Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI 48108
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001434868
About

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company focuses on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. It is in business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The company was founded by Roger S. Newton and Charles L. Bisgaier on January 22, 2008 and is headquartered in Ann Arbor, MI.

Description

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading